- Home
- Equipment
- australasia
- clinical phase
Refine by
Clinical Phase Equipment Supplied In Australasia
9 equipment items found
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
VivaGel® formulated as a mucoadhesive gel (VivaGel® BV) has been approved for marketing in the European Union as a 7-day therapy for treatment and prevention of BV including its symptoms. VivaGel® BV has been shown to have efficacy for treatment of BV in a Phase 2 clinical study and was shown to achieve statistically significant cure of the signs and ...
Manufactured by:Magellan based inBox Hill North, AUSTRALIA
Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence 2023. ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery. Clinical Investigation Stage: Phase ...
Manufactured by:ARANZ Medical Limited based inChristchurch, NEW ZEALAND
A proven wound assessment and management solution for both clinical practice and clinical research. ...
Manufactured by:NeuroScientific Biopharmaceuticals Ltd. based inCottesloe, AUSTRALIA
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II. ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...
by:Atmo Biosciences based inBox Hill, AUSTRALIA
A safe and accurate way of measuring the concentration of various gases at the source of production in the gastrointestinal tract (GI tract) in ...
Manufactured by:BioDiem Ltd. based inSouth Melbourne, AUSTRALIA
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine licensing business involves out-licensing of the company’s platform technology to vaccine manufacturers for the production of intranasal vaccines for the prevention of seasonal and pandemic ...